Topics

Adding Anti-VEGF to Docetaxel Didn't Improve OS in Bladder Cancer

09:00 EST 2 Dec 2019 | MedPageToday

(MedPage Today) -- Study Authors: Daniel P. Petrylak, Ronald de Wit, et al.; Yair Lotan, Xiaosong Meng Target Audience and Goal Statement: Oncologists, urologists, primary care physicians, internists, family medicine specialists The goal of this...

Original Article: Adding Anti-VEGF to Docetaxel Didn't Improve OS in Bladder Cancer

NEXT ARTICLE

More From BioPortfolio on "Adding Anti-VEGF to Docetaxel Didn't Improve OS in Bladder Cancer"

Quick Search